Wockhardt (WOCKPHARMA) Stock Overview
Operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
WOCKPHARMA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Wockhardt Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,341.00 |
| 52 Week High | ₹1,868.80 |
| 52 Week Low | ₹1,110.05 |
| Beta | 0.85 |
| 1 Month Change | -0.33% |
| 3 Month Change | -13.43% |
| 1 Year Change | -12.42% |
| 3 Year Change | 499.46% |
| 5 Year Change | 188.92% |
| Change since IPO | 397.00% |
Recent News & Updates
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Dec 07
Wockhardt Limited's (NSE:WOCKPHARMA) Price Is Out Of Tune With Revenues
Nov 10Here's Why Wockhardt Limited's (NSE:WOCKPHARMA) CEO May Deserve A Raise
Aug 02Recent updates
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Dec 07Wockhardt Limited's (NSE:WOCKPHARMA) Price Is Out Of Tune With Revenues
Nov 10Here's Why Wockhardt Limited's (NSE:WOCKPHARMA) CEO May Deserve A Raise
Aug 02Wockhardt Limited's (NSE:WOCKPHARMA) 26% Price Boost Is Out Of Tune With Revenues
Jun 11Does Wockhardt (NSE:WOCKPHARMA) Have A Healthy Balance Sheet?
Jun 02There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 25% Price Jump
Apr 02What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling You
Dec 17Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
Nov 02What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You
Aug 20Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Jun 30Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation
Jun 22Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01Shareholder Returns
| WOCKPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.9% | -0.4% | -0.3% |
| 1Y | -12.4% | -2.2% | -2.3% |
Return vs Industry: WOCKPHARMA underperformed the Indian Pharmaceuticals industry which returned -2.2% over the past year.
Return vs Market: WOCKPHARMA underperformed the Indian Market which returned -2.3% over the past year.
Price Volatility
| WOCKPHARMA volatility | |
|---|---|
| WOCKPHARMA Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: WOCKPHARMA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: WOCKPHARMA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,296 | Murtaza Khorakiwala | www.wockhardt.com |
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy.
Wockhardt Limited Fundamentals Summary
| WOCKPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹217.90b |
| Earnings (TTM) | -₹230.00m |
| Revenue (TTM) | ₹30.07b |
Is WOCKPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WOCKPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹30.07b |
| Cost of Revenue | ₹10.96b |
| Gross Profit | ₹19.11b |
| Other Expenses | ₹19.34b |
| Earnings | -₹230.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 14, 2026
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 63.55% |
| Net Profit Margin | -0.76% |
| Debt/Equity Ratio | 47.6% |
How did WOCKPHARMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 02:46 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wockhardt Limited is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Aarthisundari Jayakumar | Batlivala & Karani Securities India Pvt. Ltd. |